Company Description
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States.
It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells.
Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor.
The company was incorporated in 2019 and is based in Millbrae, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 5, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Roger Perlmutter |
Contact Details
Address: 230 Harriet Tubman Way Millbrae, California 94030 United States | |
| Phone | 341 777 0566 |
| Website | eikontx.com |
Stock Details
| Ticker Symbol | EIKN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1861123 |
| CUSIP Number | 282564103 |
| ISIN Number | US2825641036 |
| Employer ID | 84-2807586 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Roger M. Perlmutter, M.D., Ph.D. | Chief Executive Officer, Chair and Director |
| Roy Baynes, M.D. Ph.D. | Chief Medical Officer |
| Alfred Bowie, Ph.D. | Chief Financial Officer |
| Michael Klobuchar | Chief Operating Officer |
| Benjamin Thorner | Chief Business Officer and General Counsel |
| Dror Berman | Director |
| Leon Chen, Ph.D. | Director |
| Kenneth C. Frazier | Director |
| Robert Huffines | Director |
| David Meline | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2026 | SCHEDULE 13G | Filing |
| Feb 12, 2026 | SCHEDULE 13D | Filing |
| Feb 11, 2026 | SCHEDULE 13G | Filing |
| Feb 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 6, 2026 | 8-K | Current Report |
| Feb 5, 2026 | 424B4 | Prospectus |
| Feb 4, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Feb 4, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jan 30, 2026 | EFFECT | Notice of Effectiveness |
| Jan 28, 2026 | 8-A12B | Registration of securities |